William D. Waddill Sells 8,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $47.02 on Friday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 19.27 and a beta of 2.17. The firm has a fifty day moving average price of $39.76 and a two-hundred day moving average price of $33.19. Protagonist Therapeutics, Inc. has a fifty-two week low of $13.72 and a fifty-two week high of $47.15.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The company had revenue of $4.17 million during the quarter, compared to analyst estimates of $40.00 million. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PTGX. Truist Financial started coverage on shares of Protagonist Therapeutics in a research note on Monday, September 9th. They issued a “buy” rating and a $60.00 target price for the company. HC Wainwright lifted their price objective on shares of Protagonist Therapeutics from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. StockNews.com upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, BTIG Research upped their price target on Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $47.33.

Hedge Funds Weigh In On Protagonist Therapeutics

Several large investors have recently added to or reduced their stakes in PTGX. Hennion & Walsh Asset Management Inc. raised its stake in shares of Protagonist Therapeutics by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 34,895 shares of the company’s stock valued at $1,010,000 after purchasing an additional 849 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Protagonist Therapeutics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 14,345 shares of the company’s stock valued at $415,000 after buying an additional 1,206 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Protagonist Therapeutics during the 1st quarter worth about $35,000. Lazard Asset Management LLC bought a new position in shares of Protagonist Therapeutics during the 1st quarter worth about $69,000. Finally, CANADA LIFE ASSURANCE Co increased its stake in Protagonist Therapeutics by 74.2% in the first quarter. CANADA LIFE ASSURANCE Co now owns 9,083 shares of the company’s stock valued at $263,000 after acquiring an additional 3,870 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.